治疗模式识别受体激动剂治疗慢性乙型肝炎的：为治疗现状

StephenW

Antiviral Res. 2015 Jul 20. pii: S0166-3542(15)00169-2. doi: 10.1016/j.antiviral.2015.07.006. [Epub ahead of print]
Treatment of chronic hepatitis B with pattern recognition receptor agonists: Current status and potential for a cure.Chang J1, Guo JT2.
Author information

• 1Department of Experimental Therapeutics, The Baruch S. Blumberg Institute, Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, PA 18902, USA. Electronic address: [email protected].
• 2Department of Experimental Therapeutics, The Baruch S. Blumberg Institute, Hepatitis B Foundation, 3805 Old Easton Road, Doylestown, PA 18902, USA.
  

AbstractHepatitis B virus (HBV) has been considered to be a "stealth virus" that induces negligible innate immune responses during the early phase of infection. However, recent studies with newly developed experimental systems have revealed that virus infection can be recognized by pattern recognition receptors (PRR), eliciting a cytokine response that controls the replication of the virus. The molecular mechanisms by which interferons and other inflammatory cytokines suppress HBV replication and modulate HBV cccDNA metabolism and function are just beginning to be revealed. In agreement with the notion that the developmental and functional status of intrahepatic innate immunity determines the activation and maturation of the HBV-specific adaptive immune response and thus the outcome of HBV infection, pharmacological activation of intrahepatic innate immune responses with TLR7/8/9 or STING agonists efficiently controls HBV infection in preclinical studies and thus holds great promise for the cure of chronic hepatitis B. This article forms part of a symposium in Antiviral Research on "An unfinished story: from the discovery of the Australia antigen to the development of new curative therapies for hepatitis B."
Copyright © 2015. Published by Elsevier B.V.


KEYWORDS: Cytokine; Hepatitis B virus; Innate immune response; Pattern recognition receptor agonist

StephenW

抗病毒水库。 2015年20月PII：S0166-3542（15）00169-2。 DOI：10.1016 / j.antiviral.2015.07.006。 [打印EPUB的提前]
治疗模式识别受体激动剂治疗慢性乙型肝炎的：为治疗现状和潜力。
昌J1，郭JT2。
作者信息

    实验治疗学教研室，巴鲁克S. Blumberg的研究所，乙型肝炎基金会，3805老伊斯顿路，多伊尔斯敦，PA 18902，USA。电子地址：[email protected]。
    实验治疗学教研室，巴鲁克S. Blumberg的研究所，乙型肝炎基金会，3805老伊斯顿路，多伊尔斯敦，PA 18902，USA。

抽象

乙型肝炎病毒（HBV）已被认为是一个“隐形病毒”，在感染的早期阶段诱导微不足道先天免疫反应。然而，最近的研究，新开发的实验系统揭示，病毒感染可通过模式识别受体（PRR），引发细胞因子响应，控制病毒的复制被识别。由干扰素等炎性细胞因子抑制HBV的复制和调节HBV cccDNA的代谢和功能的分子机制才刚刚开始显露出来。与概念，即肝内先天免疫的发育和功能状态确定的激活和HBV特异性适应性免疫应答的成熟，因此HBV感染的结果，与TLR7肝内先天免疫反应/ 8/9或药理学的激活协议STING激动剂有效控制乙肝病毒感染的临床前研究，从而为持有慢性乙型肝炎的治疗本文形式的抗病毒研究的专题讨论会的一部分，对“一个未完成的故事，伟大的承诺：从澳大利亚抗原的发现到新的发展根治疗法为乙型肝炎“

版权所有©2015年出版由Elsevier B.V.
关键词：

细胞因子;乙型肝炎病毒;先天免疫应答;模式识别受体激动剂